Dr. Johannes Zuber, MD
Group Leader (PI), Research Institute of Molecular Pathology (IMP) Contact information
Research Institute of Molecular Pathology (IMP) Office phone: +43-1-79 730 3410, Mobile: +43-676-496 7199 Education
1994 - 2001
Medical School Charité, Humboldt University of Berlin, Germany Medical board (Staatsexamen), grade 1.0 (1=best, 6=bottom) Medical graduation (Ärztliche Prüfung), grade 1.16 (1=best, 6=bottom) Definite physician license (Approbation als Arzt) Doctoral Thesis; Department of Molecular Tumor Pathology, Charité, Humboldt Univer- sity of Berlin; Laboratory of Reinhold Schäfer (PhD) Project title: “A genome-wide survey of Ras transformation targets” Dr. med. (Doktor der Medizin), Humboldt-University of Berlin, Germany Final grade: summa cum laude Positions and Appointments
2001 - 2005
Clinical Residency (Arzt im Praktikum & Assistenzarzt) in Hematology and Oncology, Charité/ Virchow-Klinikum University Hospital, Berlin, Germany Clinical training in general oncology, hematology and hemostaseology, high-dose chemo-therapy and stem cell transplantation, intensive care medicine. Postdoctoral Research Fellow, Laboratory of Scott W. Lowe (PhD), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA Clinical Fellow, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA Main research interests: Development of in-vivo RNAi technologies and cancer mouse mod- els. Multiplexed negative selection RNAi screening to identify and evaluate therapeutic tar-gets. Chromatin modifier genes in progression and maintenance of AML and other cancers. Group Leader (PI) at the Research Institute of Molecular Pathology (IMP), Vienna Biocenter, Vienna, Austria
Fellowships and Awards
1994 - 2001
German Scholarship Foundation (Studienstiftung des Deutschen Volkes) Ambassador Felix Schnyder Grant (Lauri Strauss Leukemia Foundation) Scholar-in-training Award der AACR Keystone Symposia Scholarship Andrew Seligson Memorial Clinical Fellowship Publications (in reverse chronological order; *indicates equal contribution)
Dow, L.E.*, Premsrirut, P.K.*, Zuber, J.*, Fellmann, C., McJunkin, K., Miething, C., Park, Y., Dickins, R.A., Hannon, G.J., and
Lowe, S.W. (2012). A pipeline for the generation of shRNA transgenic mice. Nature Protocols 7, 374-393.
Glaser, S.P., Lee, E.F., Trounson, E., Bouillet, P., Wei, A., Fairlie, W.D., Izon, D.J., Zuber, J., Rappaport, A.R., Herold, M.J., Alexan-
der, W.S., Lowe, S.W., Robb, L., and Strasser, A. (2012). Anti-apoptotic Mcl-1 is essential for the development and sustained
growth of acute myeloid leukemia. Genes Dev 26, 120-125.
Elling, U., Taubenschmid, J., Wirnsberger, G., O'Malley, R., Demers, S.P., Vanhaelen, Q., Shukalyuk, A.I., Schmauss, G.,
Schramek, D., Schnuetgen, F., von Melchner, H., Ecker, J.R., Stanford, W.L., Zuber, J., Stark, A., and Penninger, J.M. (2011).
Forward and reverse genetics through derivation of haploid mouse embryonic stem cells. Cell Stem Cell 9, 563-574.
Zuber, J.*, Shi, J.*, Wang, E., Rappaport, A.R., Herrmann, H., Sison, E.A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., Taylor,
M.J., Johns, C., Chicas, A., Mulloy, J.C., Kogan, S.C., Brown, P., Valent, P., Bradner, J.E., Lowe, S.W., and Vakoc, C.R. (2011). RNAi
screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528.
Zuber, J.*, Rappaport, AR.*, Luo, W., Wang, E., Chen, C., Vaseva, AV., Shi, J., Weissmueller, S., Fellmann, C., Taylor, MJ.,
Graeber, TG., Kogan, S.C., Vakoc, CR., Lowe, SW. (2011). An integrated approach to dissecting oncogene addiction implicates
a Myb coordinated self-renewal program as essential for leukemia maintenance Genes Dev 25(15):1628-40
Fellmann, C.*, Zuber, J.*, McJunkin, K., Chang, K., Malone, CD., Dickins, RA., Xu, Q., Hengartner, MO., Elledge, SJ., Hannon,
GJ., Lowe, SW. (2011). Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Molecular
McJunkin, K., Mazurek, A., Premsrirut, PK., Zuber, J., Dow, LE., Simon, J., Stillman, B., Lowe, SW. (2011). Reversible suppres-
sion of an essential gene in adult mice using transgenic RNA interference. Proc Natl Acad Sci U S A 108(17):7113-8
Pardee, TS., Zuber, J., Lowe, SW. (2011). Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent
manner. Exp Hematol. 39(4):473-485.e4
Premsrirut, PK.*, Dow, LE.*, Kim, SY., Camiolo, M., Malone, CD., Miething, C., Scuoppo, C., Zuber, J., Dickins, RA., Kogan, SC.,
Shroyer, KR., Sordella, R., Hannon, GJ., Lowe, SW. (2011). A rapid and scalable system for studying gene function in mice us-
ing conditional RNA interference. Cell 145(1):145-58
Zuber, J.*, McJunkin, K.*, Fellmann, C., Dow, LE., Taylor, MJ., Hannon, GJ., Lowe, SW. (2011). Toolkit for evaluating genes re-
quired for proliferation and survival using tetracycline-regulated RNAi. Nature Biotechnology 29(1):79-83
Mavrakis, KJ., Wolfe, AL., Oricchio, E., Palomero, T., de Keersmaecker, K., McJunkin, K., Zuber, J., James, T., Khan, AA., Leslie,
CS., Parker, JS., Paddison, PJ., Tam, W., Ferrando, A., Wendel, HG. (2010). Genome-wide RNA-mediated interference screen
identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nature Cell Biology 12(4):372-9
Zhao, Z.*, Zuber, J.*, Diaz-Flores, E., Lintault, L., Kogan, SC., Shannon, K., Lowe, SW. (2010). p53 loss promotes acute myeloid
leukemia by enabling aberrant self-renewal. Genes Dev 24(13):1389-402
Blobel, GA., Kadauke, S., Wang, E., Lau, AW., Zuber, J., Chou, MM., Vakoc, CR. (2009). A reconfigured pattern of MLL occu-
pancy within mitotic chromatin promotes rapid transcriptional reactivation following mitotic exit. Molecular Cell 36(6):970-
Bric, A.*, Miething, C.*, Bialucha, CU.*, Scuoppo, C., Zender, L., Krasnitz, A., Xuan, Z., Zuber, J., Wigler, M., Hicks, J., McCombie,
RW., Hemann, MT., Hannon, GJ., Powers, S., Lowe, SW. (2009). Functional identification of tumor-suppressor genes through
an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 16(4):324-35
Guo, X., Keyes, WM., Papazoglu, C., Zuber, J., Li, W., Lowe, SW., Vogel, H., Mills, AA. (2009). TAp63 induces senescence and
suppresses tumorigenesis in vivo. Nat Cell Biology. 11(12):1451-7
Zuber, J., Radtke, I., Pardee, TS., Zhao, Z., Rappaport, AR., Luo, W., McCurrach, ME., Yang, MM., Kogan, SC., Downing, JR.,
Lowe, SW. (2009). Mouse models of human AML accurately predict chemotherapy response. Genes Dev 23(7):877-89
Zender, L.*, Xue, W.*, Zuber, J., Semighini, CP., Krasnitz, A., Ma, B., Zender, P., Kubicka, S., Luk, JM., Schirmacher, P.,
McCombie, WR., Wigler, M., Hicks, J., Hannon, GJ., Powers, S., Lowe, SW. (2008). An oncogenomics-based in vivo RNAi screen
identifies tumor suppressors in liver cancer. Cell 135(5):852-64
Zender, L., Zuber, J., Lowe, SW. (2007). Snapshot: genetic mouse models of cancer. Cell 129(4):838
Tchernitsa, OI., Sers, C., Zuber, J., Hinzmann, B., Grips, M., Schramme, A., Lund, P., Schwendel, A., Rosenthal, A., Schäfer, R.
(2004). Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. Oncogene
Trappe, RU., Riess, H., Lippek, F., Plotkin, M., Schumacher, V., Royer-Pokora, B., Hildebrandt, B., Zuber, J., Mapara, MY., Oertel,
S., Dörken, B. (2004). Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms'
tumor and a novel alteration in intron 1 of the WT1 gene. J Pediatr Hematol Oncol 26(12):820-3
Baskaynak, G., Kreuzer, KA., Schwarz, M., Zuber, J., Audring, H., Riess, H., Dörken, B., le Coutre, P. (2003). Squamous cutane-
ous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. Eur J Haematol
Schäfer, R., Tchernitsa, OI., Zuber, J., Sers, C. (2003). Dissection of signal-regulated transcriptional modules by signaling
pathway interference in oncogene-transformed cells. Adv Enzyme Regul 43:379-91
Sers, C., Tchernitsa, OI., Zuber, J., Diatchenko, L., Zhumabayeva, B., Desai, S., Htun, S., Hyder, K., Wiechen, K., Agoulnik, A.,
Scharff, KM., Siebert, PD., Schäfer, R. (2002). Gene expression profiling in RAS oncogene-transformed cell lines and in solid
tumors using subtractive suppression hybridization and cDNA arrays. Adv Enzyme Regul 42:63-82
Zuber, J.*, Tchernitsa, OI.*, Hinzmann, B., Schmitz, AC., Grips, M., Hellriegel, M., Sers, C., Rosenthal, A., Schäfer, R. (2000). A
genome-wide survey of RAS transformation targets. Nature Genetics 24(2):144-52
Tchernitsa, OI., Zuber, J., Sers, C., Brinckmann, R., Britsch, SK., Adams, V., Schäfer, R. (1999). Gene expression profiling of fi-
broblasts resistant toward oncogene-mediated transformation reveals preferential transcription of negative growth regula-
tors. Oncogene 18(39):5448-54
Selected Presentations
Keystone Meeting: Mouse Models at the Frontiers of Cancer Discovery. Whistler, Canada, poster presentation Aspen Cancer Conference 2007, Aspen, USA, poster Mouse-Models of Human Cancer, Washington, D.C., USA, talk AACR, San Diego, USA, poster Mechanisms & Models of Cancer, Cold Spring Harbor, NY, USA, talk Keystone Meeting: Targeted Cancer Therapies, Whistler, Canada, talk and poster presentation Aspen Cancer Conference 2010, Aspen, USA, poster Mechanisms & Models of Cancer, Cold Spring Harbor, NY, USA, talk 6th Microsymposium on Small RNAs, Vienna, Austria, talk EMBO Workshop Synthetic Lethality, Vienna, Austria, talk Working Conference on Cancer Stem Cells 2011, Vienna, Austria, talk ISREC Symposium 2011, Hallmarks and Horizons of Cancer, Lausanne, Switzerland, talk OeGMBT Annual Meeting 2011, Salzburg, Austria, talk Karolinska Institutet, Stockholm, Sweden, invited seminar Boehringer International Biology Meeting, Vienna, Austria, talk CRG, Barcelona, Spain, invited seminar Comprehensive Cancer Center Mainfranken, Marburg/Würzburg, Germany, invited seminars AACR Educational Session, Chicago, USA, talk DFG Hinterzartener Kreis Annual Meeting, Como, Italy, talk EMBL, Monterotondo, Italy, invited seminar NKI, Amsterdam, Netherlands, invited seminar Nachweis von differenzieller Genexpression (PCT/EP2001/001003) High Throughput Methods for Functionally Determining RNA Interference Efficiency (PCT/US2008/081193) Identification of RNAi Targets and Use of RNAi for Rational Therapy of Chemotherapy-Resistant Leukemia and Other Cancers (PCT/US2010/029083) Compositions and Methods for Treating Leukemia (PCT/US2011/036672)

Source: http://www.imp.ac.at/fileadmin/imp/Documents/CVs/2012/Zuber_CV.pdf

Microsoft word - synthesis of aspirin and acetaminophen.doc

PREPARATION OF ASPIRIN AND ACETAMINOPHEN 1996 by David A. Katz. All rights reserved. Reproduction permitted for education purposes as long as original copyright is included. OBJECT To synthesize some common pain relievers: aspirin and acetaminophen. To determine the purity of the aspirin or acetaminophen. THEORY Aspirin, acetylsalicylic acid, was first synthesized in 1893 by

Microsoft word - capsule du 25 nov. 2010

CAPSULE ÉLECTRONIQUE PHARMABIO DÉVELOPPEMENT ÉDITION DU 25 NOVEMBRE 2010 www.pharmabio.qc.ca TABLE DES SECTIONS CAPSULE ÉLECTRONIQUE PHARMABIO DÉVELOPPEMENT ÉDITION DU 25 NOVEMBRE 2010 www.pharmabio.qc.ca EMPLOIS ET MAIN D’ŒUVRE Pharmaceutiques: nouveaux licenciements au Québec (Montréal) Les licenciements se poursu

© 2010-2018 Modern Medicine